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Summary.-A fraction showing tumour-associated antigenic properties has been
isolated from pleural effusions of patients with squamous-cell carcinoma of the
lung. Purification of the material was accomplished by ion-exchange and affinity
chromatography, and by immunoabsorbents. The antigenic activity was monitored
by its inhibitory capacity in a specific complement-dependent cytotoxic system. The
final fraction has a mol. wt. of -1 7 x 105, asjudged bygelfiltration on Sephadex G200,
and the main component appears to be a glycoprotein with N-acetyl-D-glucosamine
groups. The most purified antigen preparation exhibited a highly selective capacity
to inhibit in the cytotoxic assay and to bind, when labelled with 1251, to 2 specific
antisera. The active fractions isolated from pleural effusions fully crossreacted with
fractions prepared from squamous-cell carcinoma extracts. CEA and bacterial
antigens were not detected in the material, and the presence of x-fetoprotein, HLA
and blood-group antigens may be ruled out on account of their respective molecular
weights.
IN RECENT years a number of papers
have been published dealing with tumour-
associated antigens (TAAs) isolated from
human bronchogenic cancers (Hollinshead
et al., 1974; Frost et al., 1975; Granlund
and Ritts, 1976; McCoy et al., 1977; Kelly
and Levy, 1977). The results showed a
confusing variety in biochemical details
(molecular-weight range, and electro-
phoretic mobility) as well as the TAA-
activity (typesandnumbersofspecificities,
and crossreactions) which were probably
due to the lack of standardized extraction
and purification techniques, the frequent
use of crude preparations, and the differ-
ence in activity-assessing tests. However,
it generally emerged from the body of
investigations that TAA(s) appear to
occur in pulmonary cancers and might be
obtained in a purified form by suitable
fractionation methods.
Starting material for most ofthe present
purification experiments was the pleural
effusion from patients with squamous-cell
carcinoma of the lung. Pleural effusions
avoided damaging extraction procedures,
and the volumes allowed work with the
same material over a longer period oftime
with repetition and improvement of
methods of preparation.
MATERIALS AND METHODS
Antisera.-Anti-lung-carcinoma sera were
raised in rabbits by cell suspensions prepared
from biopsy tissues of squamous-cell carcin-
oma patients. The first injection (0 5 ml of
packed cells at a time) was given i.m. into
the thigh followed by 3 i.v. injections at
weekly intervals. No adjuvants were used.
The rabbits were bled 10 days after the last
injection by heart puncture under anaes-
thesia. This antiserum was code-named BL.
An anti-normal-lung serum was produced in
the same way. Other antisera were raised by
fractions of pleural effusions. Four injections,
containing 1-5 mg protein each, were given
i.m. or i.d. respectively, with Freund's com-
plete adjuvants, over a period of4 weeks. The
antiserum used in the present study wasTAA FROM LUNG-CANCER PATIENTS
prepared with a fraction absorbed by a Con A
column (cf. Results Section). It was desig-
nated DU.
Antisera to acute lymphocytic leukeamia
(ALL), to chronic lymphocytic leukaemia
(CLL) and to normal human lymphocytes,
were produced in rabbits in a similar way to
that described above, with cells which had
been kept in liquid N2.
A polyvalent antiserum to human total
serum proteins raised in the pig, an antiserum
to human foetal proteins raised in the rabbit
and several precipitating antisera to species
immunoglobulins were obtained from Bio-
genzia Lemania SA, Switzerland.
Absorptions of antisera and antigens.-
Absorptions were carried out with cells or
finely minced tissues, and/or with normal
human sera (NHS) or antisera crosslinked by
glutaraldehyde. Absorptions by cells were
performed v/v for 45 min at room tempera-
ture, and for 45 min at 4°C. Absorptions by
crosslinked materials were done 3 times v/v
for 1 h at 4°C.
Tissue-culture cells.-Cells were provided
by our own tissue-culture department. E14
cells are a line derived from a squamous-cell
carcinoma of the human lung. The cyto-
genetic properties ofthe established line have
recently been reported (Fischer and Vetter-
lein, 1977). For control tests, batches were
used of cell lines from an osteosarcoma,
a spindle-cell sarcoma, a melanoma and
foetal-lung fibroblasts, all of human origin.
Cells from patients.-Cell batches of acute
lymphocytic leukaemia (ALL) of chronic
lymphocytic leukaemia (CLL) and of human
lymphocytes from normal individuals had all
been stored in liquid N2-
Pleural effusions.-Samples from patients
with squamous-cell carcinoma of the lung
were kindly supplied by Lainz Hospital,
Vienna. They were obtained by sterile
puncture followed by immediate centrifuga-
tion to remove all cellular and particulate
material. The clear samples were stored at
-20°C until use.
Tumour and E14 extracts.-Cell extracts
prepared by phosphate-buffered saline (PBS)
were sonicated and centrifuged at 48,000
rev/min for 1 h.
Monitoring of TAA activity.-The widely
used test is based on the inhibition of a C'-
dependent cytotoxic antiserum. For the
present study it was applied as described
previously (Wolf and Steele, 1975). Briefly,
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test fractions were incubated overnight at
4°C with a specific antiserum suitably
absorbed and diluted. After that, 51Cr-
labelled target cells followed by diluted
guinea-pig complement were added and the
reaction mixture was incubated at 37°C for
45 min. Ice-cold medium was then added, the
samples were centrifuged to remove the cell
debris, and an aliquot ofthe supernatant was
counted in a Gamma Scintillation Spectro-
meter (Packard). The radioactivity released
was expressed as a percentage of the radio-
activity released by the antiserum only,
and was used as parameter for the relative
inhibitory capacity of the fraction.
Labelling of antigen with Na 125I.-A
modification of the chloramine-T method of
Hunter (1974) has been used (Wolf et al.,
1976) without attempting to obtain aproduct
of high specific radioactivity. To a 3 ml flask,
containing 25 ,ul ofantigen (10-20 ,ug protein)
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FIG. 1. Characterization of the BL anti-
serum used in the 51Cr release inhibition
technique. BL antiserum, titrated with
51Cr-labelled E14 cells, A A unab-
sorbed; 0 O absorbed on cross-
linked normal human serum; * U
absorbed by human foetal-lung fibroblasts;
* 0 absorbed on crosslinked normal
human serum and normal lung tissue;
V V absorbed by E14 cells. 100%
= total radioactivity released by freezing
and thawing. Abscissa: serum dilutions.
Equal volumes of antiserum dilutions,
labelled cells and diluted GP-complement
were incubated for 45 min at 37°C (c.f.
Methods Section). A background of 510%
is sub racted. The values are means of
duplicates of several tests.
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were added 25 ,ul phosphate buffer (01M, pH
7.4), 10 ,u Na 125J (0O5 mCi), and, under con-
stant stirring, 25 [ld chloramine-T (4 mg/ml
phosphate buffer). After 6 min, the reaction
was stopped by 25 ,u of sodium metabisul-
phite (12 mg/ml PBS) and 100 1A KI (100
mg/ml PBS), containing 1% bovine serum
albumin, were then added. In order to
separate the tagged protein (5-10 Ci/,ug
protein) from the free iodine the mixture was
immediately passed through a column of
Sephadex G 15 which had been equilibrated
with PBS and coated with a few drops of
5% bovine serum albumin.
Saturation assay with 1251-antigen.-Puri-
fiedTAApreparations, labelled with 1251odine
were tested for binding capacity to various
specific and unspecific antisera. Ten or 20 ,ul
ofthe labelled antigen and 50 Ald ofantiserum
at various dilutions were mixed in small
conical tubes (Sarstedt GmbH) and incu-
bated at 4°C. Twenty-four hours later, 100 ,A
were added of a precipitating goat antiserum
specific for the immunoglobulins of the first
antiserum in order to separate bound from
free antigen. After further 3 h at 4°C, the
samples were centrifuged, the supernatants
were completely removed and the precipitate
in the test tube was counted in a Gamma
Scintillation Spectrometer. Results were ex-
pressed as a percentage of the total counts
added to each tube and the maximal uptake
was used as parameter for comparisons.
RESULTS
The specificity of the TAA-monitoring
system
The C'-dependent cytotoxic system
consisted of the tissue-culture cells E14
(derived from a squamous-cell carcinoma
ofthe human lung) as target cells, and the
BL antiserum produced with cell suspen-
sions prepared from a surgical specimen of
squamous-cell carcinoma of the lung. A
brief account of this system has recently
been published (Wolf, 1977).
The BL antiserum was highly cytotoxic
for the E14 cells, but, a more detailed
characterization (Fig. 1) showed that
antibodies to normal human serum pro-
teins and to normal human lung tissue had
to be removed by absorption in order to
render the antiserum specific for the TAA
of squamous-cell carcinoma. Table I
demonstrates that, in the absorbed form,
the BL antiserum in fact killed prefer-
entially the specific E14 cells, showing
little cytotoxicity to unspecific normal
and tumour cells of human origin. It
was therefore assumed that the absorbed
BL antiserum would also be specifically
neutralized (inhibited) by soluble TAA of
squamous-cell carcinoma origin, and that,
combined with the E14 cells, it would
provideaspecificsystemforthe assessment
of TAA-activity during fractionation pro-
cedures.
Inhibition experiments were performed
with the absorbed BL antiserum at a final
dilution of 1: 20. For the inhibition tests,
dilutions were prepared of all fractions
according to protein content. Usually
concentrations between 1 ,ug/ml and 100
,ug/ml of protein were examined. The
most purified antigen fractions showed a
100% inhibition at 100 ,tg protein/ml. The
TABLE I.-Titrations of Specific BL Antiserum with Various 51Cr-labelled Cells
BL antiserum
Not absorbed
Absorbed on normal human
serum and normal lung tissue
51Cr cells
E14
Foetal lung fibroblasts (F 2000)
E14
Foetal lung fibroblasts (F 2000)
Melanoma (MEL 364)
Osteosarcoma (2 T)
Spindle-cell sarcoma (FCHT)
Normal human lymphocytes
Maximal cytotoxicity
(% of releasable label)*
70t
35
30
13
8
2 -5
3
0
* Releasable label is the radioactivity released by freezing and thawing.
t Mean values of 2 sets of duplicates. (A background of 10% is from all figures.)
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Pleural effusion
(Tumour extract)
(50)
dialysed/Tris-HCI, 0- IM, pH 6-5
QAE-Sephadex A 50
O0OM|O0lMIO*2M|0-3M|0*4M|0*5Mj (NaCi)
(20) (0-5) (0-5) (5) (10) (1 -0)
(0%) (0%) (5%) (30%) (5%) (0%)
+ + +1+ + +
Con A column, PBS, pH 7 -2
not absorbed,
disgarded
(2 -3)
(5%)
absorbed, eluted
by 50mM glucoside
(1-0)
(25%)
++
[A]
125I-labelled
Sephadex G 200
PBS, pH 7-2
1 5-1-8x 105
mol. wt.
<6-5x 104
mol. wt.
[B]
Wheat-germ-lectin column
PBS, pH 7-2
(1 0)
not absorbed,
discarded
(0-35)
(10%)
absorbed,
eluted by 100 mm glucosamine
(0-05)
(20%)
absorbed on
anti-human serum
proteins and
anti-lung tissue
antisera
(protein not
measurable)
(15%)
FiG. 2.-Flow diagram of the purification procedure. Average protein yields (mg) estimated by Folin- Ciocalteus phenol reagent, and % inhibition in the 51Cr assay are given in brackets. + inhibition at 100 ,ug/ml; + + inhibition at 10 ,ug/ml; d- + + inhibition at 1 ug/ml.
effect was diluted out at 300 ng protein/
ml, demonstrating a sensitivity of the test
of about 1 ,ug/ml of specific protein.
Inhibition rates of other preparations are
shown in the Flow diagram of the puri-
fication procedure (Fig. 2).
The preparation of the antigen
Antigenicfractions were chieflyprepared
from pleural effusions, although control
extracts ofsquamous-cell carcinoma tissue
and of E14 cells were fractionated in the
same way. The flow chart of the fraction-
ation procedure is shown in Fig. 2. The
starting material was dialysed against
Tris/HCl buffer, 0-iM, pH 6-5, and the
sample (3-5 ml containing up to 150 mg
protein) was applied to a QAE-Sephadex
A 50 column (1-9 x 12 cm) equilibrated
with the same Tris/HCl buffer. Stepwise
elution was performed with increasing
NaCl starting from zero concentration up
to 0-5M in Tris buffer. Activity was found
in fractions eluted by 0O2-0-4M NaCl, but
most ofit was recovered infractions eluted
by 0-2M or 0-3M NaCl. Active fractions
were concentrated by polyethylene glycol,
dialysed against phosphate-buffered saline
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(PBS) pH 7-2, and layered on to a Con
A-Sepharose (Pharmacia) column (I 0 x 8 5
cm) equilibrated with PBS, pH 7-2. The
column was washed with PBS and the
absorbed material eluted with 0-05M
ox-methyl-D-glucoside in PBS. Most of the
activity was recovered in the bound
material, which again was dialysed and
concentrated.
For further purification 2 different
methods were used.
(A) In order to obtain peak distinction
in gel filtrations (in spite of low protein
content of the fractions at that stage),
the antigen was labelled with 125iodine and
the protein fraction, after passing a Sepha-
dex G 15 gel (cf. Labelling) was layered on
to a Sephadex G 200 column (0.9 x 30 cm)
equilibrated and eluted with PBS, pH 7.2.
The elution profile showed 2 1251-peaks,
the first appearing shortly in front of
human IgG and the second shortly after
human albumin.
(B) By the second method, the active
fraction of the Con A column was applied
to a column of wheat-germ lectin (WGL)
coupled to Sepharose 6MB (Pharmacia).
This column (2 ml volume) was equilib-
rated and washed with PBS, and the
absorbed material, eluted by N-acetyl-D-
glucosamine (100 mm in PBS) was dialysed
very carefully (in order to remove all
glucosamine) and then concentrated. The
glycoproteins absorbed by the wheat
germ lectin appeared to possess high
specific inhibitory activity in the cytotoxic
assay. The preparation was iodinated and
examined for uptake by antiserum in the
saturation assay (Table II), or it was
submitted to successive absorption on
crosslinked antisera to normal human
proteins and to normal human lung tissues,
TABLE II.-Saturation Analysis Carried out with Various Antisera and 125I-labelled
Antigens
1251 Antigen
(origin and fraction type)
Pleural Effusion
Con A-bound material
Sephadex G 200
Fraction: I *5-1 - 7 x 105d
Antiserum*
BL, not absorbed
absorbed
DU, absorbed
anti-normal lung tissue, not absorbed
anti-human foetal protein, not absorbed
anti-CLL-cells, not absorbed
anti-ALL-cells, not absorbed
anti-normal human lymphocytes, not absorbed
BL, absorbed
DU, absorbed
< 6-5 x 104d BL, absorbed
DU, absorbed
Wheat germ lectin-
bound material BL, absorbed
DU, absorbed
Maximal uptake of
125I antigen (O )§
(Bound/Totalt)t
35
20
30
8
10
13
3
3
25
70
2
8
(34; 31; 36; 38; 35; 35)
(18; 19; 21; 22)
(25; 29; 30; 35)
(7; 8)
(9; 11)
(10; 17; 19; 16)
(3; 3)
(3; 3)
(21; 24; 25; 29)
(69; 70; 75; 68; 69; 76)
(2; 2)
(8; 8)
15 (14; 13; 18; 19)
55 (55; 54; 52; 53)
Squamous-cell carcinoma (cells)
Con A-bound material BL, absorbed
DU, absorbed
Material not bound BL, absorbed
DU, absorbed
15
25
0
0
(13; 15; 18; 14)
(26; 28; 24; 23)
(0; 0)
(0; 0)
E14 (cultured cells)
Con A-bound material BL, absorbed 12 (12; 10; 14; 13)
DU, absorbed 20 (19;20; 23; 21)
* Antisera were titrated in 5-fold dilutions from 1 : 20 to 1 : 62,500. Maximal uptake occurred at dilutions
1: 20-1: 100.
t In most cases the total was 20,000 ct/min. In case of the G 200 fractions it was 6000 ct/min.
: Background of 6-10% subtracted before calculation.
§ Mean values of duplicates of 1-3 tests (first column), and values of single tubes (in brackets).
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and then tested for inhibitory activity.
The protein recovery in the fraction which
was bound to the WGL-column was about
0-100 of the protein in the starting
material, and this was further reduced
(electrophoretic evidence not shown in
this paper) by absorption on crosslinked
antisera to proteins of normal human
serum and lung.
Saturation Analysis
Fractions which proved to be good
inhibitors in the cytotoxic system, along
with non-inhibiting control fractions,
were labelled with 125I and tested in a
saturation-type radioimmunoassay to
provide additional evidence for their
specificity by being selectively taken up
by the specific antiserum BL. It was,
furthermore, investigated whether the
BL antiserum (raised by tumour cells) and
the DU antiserum (raised by pleural-
effusion fractions) would exhibit similar
specific properties in this test, and whether
crossreactions would occur between both
antisera and fractions from pleural effu-
sions, tumour-cell extracts and tissue-
culture cell extracts.
It may be gathered from Table II that
the labelled antigens were taken up by
both antisera, BL and DU, the antiserum
DU being, generally, more avid than
antiserum BL. It will also be noted that
the antigen uptake was selective. Un-
specific antisera reacted much less with
the antigen preparations, in particular
the antiserum specific for normal human
lymphocytes did not bind antigen at all,
although it exhibited a good cytotoxic
titre with normal lymphocytes (unpub-
lished data). Besides, control prepara-
tions, e.g. the low-molecular-weight com-
ponent obtained from the Sephadex G 200
column, and the material which was
recovered in the void volume of the Con
A-columns, both did not attach them-
selves to either antiserum. There was also
a wide crossreaction between the antigens
isolated from squamous-cell carcinoma
tissue. pleural effusions, and the E14
culture cellsandbothantisera. No evidence
was found for astrongeruptake ofantigens
from tumour cells by the BL antiserum as
compared with the DU antiserum. These
results thus appear to prove that the
pleural effusions contain the same antigens
as occur on, and can be extracted from,
squamous-cell carcinoma cells. They also
confirm the specificity of the 51Cr test by
showing that the uptake of labelled anti-
gens corresponds principally to their
inhibitory capacity.
DISCUSSION
The BL antiserum (produced with
squamous-cell carcinoma cells ofapatient)
after exhaustive absorption on normal
human serum proteins and normal lung
tissue, still exhibited a cytolytic effect on
the E14 target cells, which could be
selectively inhibited by certain isolated
and purified materials. These inhibiting
substances may, therefore, contain speci-
fic antigens, associated with squamous-
cell carcinoma cells, which do not occur in
sera and lung tissues ofnormal individuals
(or only on very low levels).
Biochemically, theantigenwould appear
to be a glycoprotein withN-acetyl-glucos-
amine groups, which are the sugar groups
specifically bound by wheat-germ lectin.
To judge by elution profiles from gel-
filtration columns, the molecular weight
of the most purified fractions was slightly
higher than that of IgG (i.e. '1l7 X 105
dalton). After passing the WGL-column
the specific inhibitory activity of the anti-
gen preparation had increased consider-
ably, an observation perhaps due to an
effect similar to that described by Clemet-
son et al. (1976) who were able to separate
normal transplantation antigens from
tumour-specific antigens in extracts from
a murine mastocytoma on columns of
wheat-germ lectin.
During the course of the separation
procedure, it was observed that, apart
from fractions containing most of the
inhibitory activity, some others of differ-
ent constitution exhibited small inhibitory
effects. This may be due to imperfect
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separation, or to different molecules carry-
ing the same active groups. It may also
indicate genuinely dissimilar, weakly
crossreacting substances, and confirm the
existence ofvarious distinctTAA-activities
which were recently reported by Veltri et
al. (1977).
The molecular weight found for the
described isolated antigen is close to that
of carcinoembryonic antigen (CEA)
(Tillack etal., 1974). But, byradioimmuno-
assay, kindly performed by Mr B. Chaput
(Hoffman La Roche, Vienna) several crude
and purified fractions of the present series
were all negative for CEA. The presence
of ox-foetoprotein and of HLA antigens
can also be ruled out, because of their
respective molecular weights, and so may
the involvement of blood-group antigens
(mol. wt. 2-3 x 105). Finally, contamina-
tion by bacterial antigens from pleural
infections could not be detected in
the antigen fractions by an antiserum
raised to a wide bacterial spectrum.
Some caution, concerning possible cross-
reactions of antigens from certain other
tumours, appears to be, nevertheless,
appropriate. Like the anti-CLL serum
that shows a relatively high antigen
uptake in the saturation assay, the BL
antiserum produced a relatively high
cytotoxic titre with Ewing sarcoma cells.
Studies of crossreactions of the antisera
with such "unrelated" antigens, and with
"related" antigens such as TAAs from
lung cancers of different histopathological
origin, as well as the suitability of the
isolated antigen as a diagnostic marker for
lung cancer in clinical trials are now in
progress.
I wish to express my thanks to Professor H. Wrba
for generously providing the facilities for these
experiments, and to Drs M. Micksche and W. Rella
for co-operating and supplying clinical samples. The
technical assistance of H. Bauer and the preparation
of tumour and E14 extracts by E. Sandor are
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